Authors
Paolo A Ascierto, Ketty Peris, Maria C Fargnoli, Paolo Bossi, Vincenzo DE Giorgi, Lisa Licitra, Paola Savoia, Michele Guida, Francesco Spagnolo, Federica DE Galitiis, Ignazio Stanganelli, Loredana Romano, Serena Martelli, Ramon Arntz, Massimiliano Scalvenzi
Published in
Italian journal of dermatology and venereology. Sep 29, 2026. Epub Sep 29, 2026.
Abstract
Following the pivotal Phase II BOLT trial, sonidegib was approved by EMA to treat laBCC in patients not amenable to surgery or radiotherapy.
The NISSO study (NCT04066504) is a non-interventional, multinational, multi-center, long-term, post-authorization, real-world safety study. Patients with laBCC were treated with sonidegib 200 mg orally once-daily and followed for 3 years according to the Prescribing Information.
Ninety-three patients were enrolled at 12 Italian centers with a median age of 79. The median exposure to sonidegib exposure was 8.9 months. At the time of the analysis, treatment ended in 65.6% patients, mainly due to patient/guardian decision, treatment success and physician decision. Most patients (78.5%) experienced at least 1 treatment-emergent adverse event (TEAE) including muscle spasms (39.8%), dysgeusia (32.3%), fatigue (21.5%); all of them decreased substantially after 3 months. Most TEAEs were Grade 1 and led to treatment discontinuation in 12.9%, while serious drug-related TEAEs were reported in 2.1% of patients. The Italian interim analysis shows a better real-world safety profile than could be expected based on the pivotal BOLT trial. Most patients experienced the onset of common AEs after 3 months.
All the above supports the use of sonidegib as a manageable first-line systemic treatment in patients with laBCC.
PMID:
42808822
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0